A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.
Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.
Aristea Therapeutics emerged Dec. 18 with a $15 million series A round and mission revolving around inflammatory diseases.
Shares of Evofem rose on Dec. 17 after the company reported that its birth control gel worked as intended in late-stage clinical trials.
Serial biotech entrepreneur Jonathan Lim is back at it.
Aethlon Medical, a San Diego company, named Timothy Rodell as interim CEO, it was announced Dec. 13.
Nex3 will launch a new digital health accelerator in San Diego.
Technology, Talent Keep Area’s Agriculture Growing Strong
Decades ago on North County farms, the Ecke family turned the poinsettia into a top-selling Christmas plant. From former Ecke land, Cibus again wants to put the region on the map.
Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.
San Diego saw seven IPOs in 2018, largely dominated by life sciences companies.
San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.
The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?
Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.
HEALTH: Grossmont Makes Move; Palomar Considers Election Change
Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.
Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.